Hemophilia: The Paradigm Shift and the Unresolved Challenges

Dear Colleagues,

Over the past decade, hemophilia care has experienced an unprecedented paradigm shift, driven by the advancement of extended half-life concentrates, bispecific antibodies, and, more recently, gene therapy. These advances have transformed the natural history of the disease, improving life expectancy and quality of life for patients with access to treatment. However, this therapeutic revolution coexists with persistent musculoskeletal complications, chronic pain, and significant disparities in global access to care. As people with hemophilia live to an older age, age-related comorbidities are emerging as new clinical challenges. Additionally, female carriers often experience bleeding symptoms and psychological distress associated with genetic transmission. Physiotherapy, rehabilitation, and musculoskeletal ultrasound remain essential components of multidisciplinary care.

This Special Issue invites readers to explore the challenges and opportunities of comprehensive care in hemophilia, under the clinical leadership of hematology, and to study aspects such as musculoskeletal complications, diagnostic tools, quality-of-life assessment, and new models of multidisciplinary care.

We aim to encourage reflection on how to consolidate this new therapeutic paradigm without losing sight of the problems that remain unresolved. Improvements in hemophilia care should not focus solely on innovation and access to emerging therapies but also on providing equitable care that includes physical rehabilitation, psychosocial support, and sustained collaboration among specialists and patient associations worldwide.

Dr. Felipe Querol
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Hematology Reports is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.